Cargando…
SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma
Background: Cabergoline is first-line treatment for prolactin-secreting pituitary macroadenoma (prolactinoma). Side effects such as nausea, valvulopathy and neuropsychiatric symptoms are well recognized complications of its use. A rare complication is vision loss secondary to empty-sella syndrome. C...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207920/ http://dx.doi.org/10.1210/jendso/bvaa046.1151 |
_version_ | 1783530718986502144 |
---|---|
author | Díaz-Balzac, Carlos A Williams, Zoe R Vates, G Edward Shafiq, Ismat |
author_facet | Díaz-Balzac, Carlos A Williams, Zoe R Vates, G Edward Shafiq, Ismat |
author_sort | Díaz-Balzac, Carlos A |
collection | PubMed |
description | Background: Cabergoline is first-line treatment for prolactin-secreting pituitary macroadenoma (prolactinoma). Side effects such as nausea, valvulopathy and neuropsychiatric symptoms are well recognized complications of its use. A rare complication is vision loss secondary to empty-sella syndrome. Clinical case: A 27-years old women was diagnosed in 2009 with macroprolactinoma with a prolactin level of 2,523.91ng/mL (normal 3.3-26.7ng/mL), during work up of frontal headaches, amenorrhea and infertility. The rest of her pituitary work up was normal. She was started on dopamine receptor agonist therapy with Cabergoline 0.25mg two times a week. Her headaches improved within a few month. The prolactin level normalized and MRI at 1 year after starting Cabergoline therapy showed significant decrease in pituitary adenoma to 3mm. She continued Cabergoline therapy for 3 years, after which time it was discontinued. For the next 6-8 years she was on and off Cabergoline therapy for mild elevation of prolactin and galactorrhea/headache symptoms, with improvement of symptoms on Cabergoline. However, nine years after diagnosis and Cabergoline treatment, she developed vision loss, characterized by bitemporal hemianopia. MRI showed partial empty sella with downward displacement of the optic chiasm. Cabergoline therapy was stopped with some improvement of visual symptoms on exam. Here latest prolactin level is at 134ng/ml. Surgical management with chiasmapexy is being explored. Conclusion: Vision loss secondary to optic nerve traction from chiasmal herniation in the setting of an empty sella can be a consequence of Cabergoline therapy. No predictors or risk factors are known for the development of this complication. Furthermore, no clear evidence is available of benefit from discontinuation/continuation of therapy. Novel surgical management with chiasmapexy is being explored as a solution to stabilize the optic chiasm and resolve visual symptoms without further complications. |
format | Online Article Text |
id | pubmed-7207920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72079202020-05-13 SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma Díaz-Balzac, Carlos A Williams, Zoe R Vates, G Edward Shafiq, Ismat J Endocr Soc Neuroendocrinology and Pituitary Background: Cabergoline is first-line treatment for prolactin-secreting pituitary macroadenoma (prolactinoma). Side effects such as nausea, valvulopathy and neuropsychiatric symptoms are well recognized complications of its use. A rare complication is vision loss secondary to empty-sella syndrome. Clinical case: A 27-years old women was diagnosed in 2009 with macroprolactinoma with a prolactin level of 2,523.91ng/mL (normal 3.3-26.7ng/mL), during work up of frontal headaches, amenorrhea and infertility. The rest of her pituitary work up was normal. She was started on dopamine receptor agonist therapy with Cabergoline 0.25mg two times a week. Her headaches improved within a few month. The prolactin level normalized and MRI at 1 year after starting Cabergoline therapy showed significant decrease in pituitary adenoma to 3mm. She continued Cabergoline therapy for 3 years, after which time it was discontinued. For the next 6-8 years she was on and off Cabergoline therapy for mild elevation of prolactin and galactorrhea/headache symptoms, with improvement of symptoms on Cabergoline. However, nine years after diagnosis and Cabergoline treatment, she developed vision loss, characterized by bitemporal hemianopia. MRI showed partial empty sella with downward displacement of the optic chiasm. Cabergoline therapy was stopped with some improvement of visual symptoms on exam. Here latest prolactin level is at 134ng/ml. Surgical management with chiasmapexy is being explored. Conclusion: Vision loss secondary to optic nerve traction from chiasmal herniation in the setting of an empty sella can be a consequence of Cabergoline therapy. No predictors or risk factors are known for the development of this complication. Furthermore, no clear evidence is available of benefit from discontinuation/continuation of therapy. Novel surgical management with chiasmapexy is being explored as a solution to stabilize the optic chiasm and resolve visual symptoms without further complications. Oxford University Press 2020-05-08 /pmc/articles/PMC7207920/ http://dx.doi.org/10.1210/jendso/bvaa046.1151 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Neuroendocrinology and Pituitary Díaz-Balzac, Carlos A Williams, Zoe R Vates, G Edward Shafiq, Ismat SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma |
title | SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma |
title_full | SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma |
title_fullStr | SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma |
title_full_unstemmed | SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma |
title_short | SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma |
title_sort | sat-275 bitemporal hemianopia as a result of cabergoline therapy for macroprolactinoma |
topic | Neuroendocrinology and Pituitary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207920/ http://dx.doi.org/10.1210/jendso/bvaa046.1151 |
work_keys_str_mv | AT diazbalzaccarlosa sat275bitemporalhemianopiaasaresultofcabergolinetherapyformacroprolactinoma AT williamszoer sat275bitemporalhemianopiaasaresultofcabergolinetherapyformacroprolactinoma AT vatesgedward sat275bitemporalhemianopiaasaresultofcabergolinetherapyformacroprolactinoma AT shafiqismat sat275bitemporalhemianopiaasaresultofcabergolinetherapyformacroprolactinoma |